BACKGROUND: Rett syndrome is a neurodevelopmental disorder mainly affecting females. It is principally caused by mutations in the MECP2 gene. Seizures occur in about 80% of subjects but there has been little research into the factors contributing to their frequency. AIMS: To investigate seizure frequency in Rett syndrome and its relationship with other factors, including genetic characteristics and the use of anti-epileptic drugs. METHODS: Information on daily seizure occurrence and health service utilization and monthly anti-epileptic drug use was provided on 162 Rett syndrome cases for a calendar year. Age at onset of seizures, developmental history and other clinical and genetic characteristics were obtained from a contemporaneously completed questionnaire and from the Australian Rett Syndrome Database. Negative binomial regression was used to investigate factors associated with seizure rates. RESULTS: Seizure rates were highest in the 7-12 year age group. They were lower in those with p.R294X, p.R255X mutations and C terminal mutations. Those who had early developmental problems and poorer mobility had higher seizure rates as did those with greater clinical severity and poorer functional ability. Many different combinations of medications were being used with carbamazepine, sodium valproate and lamotrigine either singly or in combination with another being the most common. CONCLUSIONS: Seizure frequency in Rett syndrome is age-dependent, more common in those with more severe early developmental problems and influenced by mutation type.
BACKGROUND:Rett syndrome is a neurodevelopmental disorder mainly affecting females. It is principally caused by mutations in the MECP2 gene. Seizures occur in about 80% of subjects but there has been little research into the factors contributing to their frequency. AIMS: To investigate seizure frequency in Rett syndrome and its relationship with other factors, including genetic characteristics and the use of anti-epileptic drugs. METHODS: Information on daily seizure occurrence and health service utilization and monthly anti-epileptic drug use was provided on 162 Rett syndrome cases for a calendar year. Age at onset of seizures, developmental history and other clinical and genetic characteristics were obtained from a contemporaneously completed questionnaire and from the Australian Rett Syndrome Database. Negative binomial regression was used to investigate factors associated with seizure rates. RESULTS:Seizure rates were highest in the 7-12 year age group. They were lower in those with p.R294X, p.R255X mutations and C terminal mutations. Those who had early developmental problems and poorer mobility had higher seizure rates as did those with greater clinical severity and poorer functional ability. Many different combinations of medications were being used with carbamazepine, sodium valproate and lamotrigine either singly or in combination with another being the most common. CONCLUSIONS:Seizure frequency in Rett syndrome is age-dependent, more common in those with more severe early developmental problems and influenced by mutation type.
Authors: A M Kerr; Y Nomura; D Armstrong; M Anvret; P V Belichenko; S Budden; H Cass; J Christodoulou; A Clarke; C Ellaway; M d'Esposito; U Francke; M Hulten; P Julu; H Leonard; S Naidu; C Schanen; T Webb; I W Engerstrom; Y Yamashita; M Segawa Journal: Brain Dev Date: 2001-07 Impact factor: 1.961
Authors: Sarah Ager; Susan Fyfe; John Christodoulou; Peter Jacoby; Lincoln Schmitt; Helen Leonard Journal: J Child Neurol Date: 2006-09 Impact factor: 1.987
Authors: A M Fredriks; S van Buuren; R J Burgmeijer; J F Meulmeester; R J Beuker; E Brugman; M J Roede; S P Verloove-Vanhorick; J M Wit Journal: Pediatr Res Date: 2000-03 Impact factor: 3.756
Authors: Le Jian; Lakshmi Nagarajan; Nicholas de Klerk; David Ravine; Carol Bower; Alison Anderson; Sarah Williamson; John Christodoulou; Helen Leonard Journal: J Pediatr Date: 2006-10 Impact factor: 4.406
Authors: R E Amir; I B Van den Veyver; R Schultz; D M Malicki; C Q Tran; E J Dahle; A Philippi; L Timar; A K Percy; K J Motil; O Lichtarge; E O Smith; D G Glaze; H Y Zoghbi Journal: Ann Neurol Date: 2000-05 Impact factor: 10.422
Authors: Crystal L Laurvick; Nicholas de Klerk; Carol Bower; John Christodoulou; David Ravine; Carolyn Ellaway; Sarah Williamson; Helen Leonard Journal: J Pediatr Date: 2006-03 Impact factor: 4.406
Authors: Daniel C Tarquinio; Wei Hou; Anne Berg; Walter E Kaufmann; Jane B Lane; Steven A Skinner; Kathleen J Motil; Jeffrey L Neul; Alan K Percy; Daniel G Glaze Journal: Brain Date: 2016-12-21 Impact factor: 13.501
Authors: Jenny Downs; Sandrine M Géranton; Ami Bebbington; Peter Jacoby; Nadia Bahi-Buisson; David Ravine; Helen Leonard Journal: Am J Med Genet A Date: 2010-05 Impact factor: 2.802
Authors: Eric S Semmel; Michelle E Fox; Sabrina D Na; Rella Kautiainen; Robert D Latzman; Tricia Z King Journal: Neuropsychol Rev Date: 2019-11-20 Impact factor: 7.444